OurCrowd, Author at OurCrowd Blog

[BriefCam in PR Newswire] BriefCam Exponentially Accelerates Performance and Precision of Its Video Analytics Solutions Through NVIDIA GPUs

Sep 19, 2017 | News Center

BriefCam®, the industry’s leading provider of Video Synopsis® solutions for rapid video review and search, real-time alerting, and quantitative video insights, today announced that it’s a part of the newly launched NVIDIA Metropolis Software Partner Program. Read more on PR Newswire...

[Taranis on CNBC-TV 18] Young Turks In Tel Aviv, Israel | Part 2

Sep 18, 2017 | News Center

Watch Taranis in this Agri Tech special on CNBC-TV 18 here.

[CropX on CNBC-TV 18] Young Turks In Tel Aviv, Israel | Part 1

Sep 18, 2017 | News Center

Watch CropX in this Agri Tech special at minute 8:25 here.

[EdenShield on CNBC-TV 18] Young Turks In Tel Aviv, Israel | Part 2

Sep 18, 2017 | News Center

Watch EdenShield in this Agritech special at minute 5:13 here.

[MeMed in PR Newswire] MeMed Completes Trilogy of Clinical Studies with More Than 2,000 Patients Validating First Ever Blood Test to Accurately Distinguish Between Bacterial and Viral Infections

Sep 18, 2017 | News Center

MeMed today announced positive results from a large, external double-blinded PATHFINDER study that met its primary endpoint, independently confirming that MeMed’s novel blood test, ImmunoXpert™, accurately distinguishes between bacterial and viral infections in children. Read more on PR...

Author: OurCrowd

[BriefCam in PR Newswire] BriefCam Exponentially Accelerates Performance and Precision of Its Video Analytics Solutions Through NVIDIA GPUs

[Taranis on CNBC-TV 18] Young Turks In Tel Aviv, Israel | Part 2

[CropX on CNBC-TV 18] Young Turks In Tel Aviv, Israel | Part 1

[EdenShield on CNBC-TV 18] Young Turks In Tel Aviv, Israel | Part 2

[MeMed in PR Newswire] MeMed Completes Trilogy of Clinical Studies with More Than 2,000 Patients Validating First Ever Blood Test to Accurately Distinguish Between Bacterial and Viral Infections

Recent Posts